Precigen

Precigen

Biotechnology
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

$1.5B

Market Cap • 11/20/2026

1998

(28 years)

Founded

2013

(13 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

18

P/S

9,6

P/EBITDA

39,6

P/OCF

—

P/FCF

—

P/E

42,1

BVPS

0,2

EPS

0,1

Market Cap

Market Cap

1,5B

EV

1,6B

EV/Revenue

10

EV/EBITDA

41

EV/EBIT

46,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-2,3B

Profitability

Gross Margin

91,4%

EBITDA Margin

24,3%

EBIT Margin

21,4%

Net Margin

15,8%

D&A/EBITDA

0%

R&D/Revenue

16,9%

Capex/Revenue

0,7%

Capex/D&A

24,8%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

8,2%

% Goodwill

7,2%

ROE

39,5%

ROIC

37,5%

Growth

CAGR Revenue 5Y

25,2%

CAGR Op. Income 5Y

9,4%

CAGR Net Income 5Y

50,1%

CAGR OCF 5Y

4,9%

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

5,6

Quick Ratio

4,6

Interest Coverage

284,5%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium